Literature DB >> 39974

CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.

P Riederer, W D Rausch, W Birkmayer, K Jellinger, D Seemann.   

Abstract

Tyrosine hydroxylase (TH) activity was assayed radioenzymatically in various regions of post-mortem brains of human individuals without neurologic disorders (controls), with Parkinson's disease, senile dementia, hypertensive encephalopathy, hepatic and diabetic coma, liver cirrhosis without coma, and hepatic coma treated with parenteral administration of L-valine. In addition TH activity of the post-mortem adrenal medulla was assayed in controls, in Parkinson's disease, senile dementia and hypertensive encephalopathy. In Parkinson's disease TH activity was significantly decreased in the nigrostriatal system, and less severe in other brainstem areas, while the raphé-reticular formation and limbic system showed normal values. In addition, there was significant decrease in the TH activity of the adrenal medulla, suggesting that Parkinson's disease is a generalized disorder not limited to distinct CNS areas, and that impairment of the dopaminergic niggro-striatal system may involve the TH activity in the adrenal medulla, thus inducing disorders of the peripheral sympathetic system. Senile brain atrophy showed no definite changes in brain, except the striatum, and adrenomedullary TH, while in one case of hypertensive encephalopathy due to long-term corticosteroid treatment normal TH activity in the adrenal medulla was opposed by decreased striatal TH activity, probably due to cerebral ischemia. TH activity in the caudate nucleus of individuals with both hepatic and diabetic coma were within normal ranges, suggesting a sufficient energy supply of the brain during such metabolic catastrophes, while reduced brain TH activity in patients with hepatic coma who died of acute gastrointestinal bleeding is probably due to severe final cerebral ischemia. No correlative data on brain and adrenomedullary TH activities in metabolic encephalopathies are available so far.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 39974

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  13 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 3.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

4.  Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from parkinsonian patients.

Authors:  P Cervera; O Rascol; A Ploska; G Gaillard; R Raisman; C Duyckaerts; J J Hauw; D Scherman; J L Montastruc; F Javoy-Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

5.  Parkinson's disease putamen: normal concentration of synaptic membrane marker antigens.

Authors:  O S Jørgensen; G P Reynolds; P Riederer; K Jellinger
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

Review 6.  Is NADH effective in the treatment of Parkinson's disease?

Authors:  R H Swerdlow
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

7.  Transient supression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla.

Authors:  O P Yntema; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.

Authors:  C T Chopde; M S Hote; S N Mandhane; A V Muthal
Journal:  J Neural Transm Gen Sect       Date:  1995

9.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients.

Authors:  M Sawada; T Nagatsu; I Nagatsu; K Ito; R Iizuka; T Kondo; H Narabayashi
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.